Core Viewpoint - Switzerland has ranked first in the global innovation index for 13 consecutive years since 2011, making it a significant innovation hub and China's first strategic partner in innovation [1] Group 1: Company Overview - Tandem Therapeutics, founded in 2023, focuses on developing novel peptide-drug conjugates specifically targeting fibrotic matrices to provide new precision treatment options for fibrosis and fibrotic cancers [2][4] - The company is a spin-off from ETH Zurich, co-founded by Mamta Chabria, Viola Vogel, and Martin Behe, who have extensive backgrounds in biology and biophysics [2][6] Group 2: Technology and Research - Tandem's technology is based on over 15 years of research from ETH Zurich and the Paul Scherrer Institute, utilizing a comprehensive understanding of matrix mechanobiology to develop treatments for fibrosis [6][7] - The company aims to target the mechanical changes in fibrotic extracellular matrices, which are critical drivers of fibrosis progression, using peptide-drug conjugates that offer non-immunogenicity and cost-effectiveness compared to antibodies [8] Group 3: Market Potential and Development - Fibrosis is a significant medical challenge, accounting for over 45% of mortality in developed countries, with current treatments unable to fully halt or reverse the condition [4] - Tandem's lead project focuses on progressive pulmonary fibrosis, with preclinical efficacy being validated in mouse and human lung fibrosis models [8] - The company has received CHF 150,000 in funding from Venture Kick and joined the Wyss Zurich Translational Center to advance its research and development efforts [8]